It will therefore be relevant to test in future studies if EZH2 inhibitors, which are currently in clinical development for prostate cancer, can be used to pharmacologically enhance the expression of these cell surface antigens and, therefore, increase tumor targeting. The gene discussed is CD53; the disease is prostate cancer.